Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03251859 | Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study | PHASE3 | COMPLETED | 52 | — | — | Aug 11, 2017 | Feb 23, 2018 | Apr 21, 2023 | 1 | Poland |
Platelet inhibition evaluated with the VASP assay 45 days after myocardial infarction.
| Arm | Type | Description |
|---|---|---|
| Standard ticagrelor maintenance dose | ACTIVE_COMPARATOR | Ticagrelor 90 mg twice daily for the first 45 days after myocardial infarction treated with percutaneous coronary intervention. |
| Reduced ticagrelor maintenance dose | EXPERIMENTAL | Ticagrelor 90 mg twice daily for the first 30 days after myocardial infarction treated with percutaneous coronary intervention, then reduction of the maintenance dose to ticagrelor 60 mg twice daily for the next 15 days. |
| Name | Type | Description |
|---|---|---|
| Ticagrelor 90 mg | DRUG | Ticagrelor 90 mg twice daily |
| Ticagrelor 60 mg | DRUG | Ticagrelor 60 mg daily |
Inclusion Criteria: * provision of informed consent prior to any study specific procedures * diagnosis of acute ST-segment elevation myocardial infarction or acute non-ST-segment elevation myocardial infarction according to the Third Universal Definition of Myocardial Infarction * index event treat...